Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio (NYSE: ANVS) has regained compliance with New York Stock Exchange listing standards a year after falling below required market capitalization and stockholders’ equity thresholds, removing …
Annovis Regains NYSE Compliance Ahead of Listing Deadline Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported that enrollment in its pivotal Phase 3 Alzheimer’s disease trial has reached 85% and remains on track for completion this summer, …
Annovis Nears Full AD Enrollment Ahead of NDA Plans Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently published results from a Phase 2/3 clinical trial evaluating its investigational drug buntanetap in patients with mild to moderate Alzheimer’s disease, …
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received a U.S. patent covering the use of its drug candidate buntanetap to prevent and treat neurological injuries linked to brain …
Annovis Secures U.S. Patent for Buntanetap Neurological Use Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article detailing the development of its lead drug candidate buntanetap as the company continues clinical trials for …
Annovis Bio Highlights Buntanetap Development in Published Article Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has partnered with NeuroRPM to integrate an FDA-cleared artificial intelligence platform into its ongoing Parkinson’s disease study to improve symptom monitoring and …
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) reported its 2025 financial results and said it advanced late-stage clinical development of its investigational drug buntanetap, including launching a Phase 3 …
Annovis Reports 2025 Results, Advances Buntanetap Trials Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced it will present two research updates on its investigational drug buntanetap at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases, …
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has recommended continuation of its ongoing Phase 3 clinical trial of buntanetap in …
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will begin enrolling patients in January 2026 in a large, long-term study designed to assess whether its experimental Parkinson’s disease …
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug Read More